These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 35834124)

  • 1. Nemolizumab: First Approval.
    Keam SJ
    Drugs; 2022 Jul; 82(10):1143-1150. PubMed ID: 35834124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological profiles and clinical findings of nemolizumab as treatment for pruritus associated with atopic dermatitis].
    Kaneda N
    Nihon Yakurigaku Zasshi; 2023; 158(3):282-289. PubMed ID: 37121713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.
    Serra-Baldrich E; Santamaría-Babí LF; Francisco Silvestre J
    Actas Dermosifiliogr; 2022; 113(7):674-684. PubMed ID: 35842249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
    Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C
    N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab.
    Tsoi LC; Hacini-Rachinel F; Fogel P; Rousseau F; Xing X; Patrick MT; Billi AC; Berthier CC; Kahlenberg JM; Lazzari A; Wiegmann H; Ständer S; Piketty C; Julia V; Krishnaswamy JK; Gudjonsson JE
    J Allergy Clin Immunol; 2022 Apr; 149(4):1329-1339. PubMed ID: 34857395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
    Kwatra SG; Yosipovitch G; Legat FJ; Reich A; Paul C; Simon D; Naldi L; Lynde C; De Bruin-Weller MS; Nahm WK; Sauder M; Gharib R; Barbarot S; Szepietowski JC; Conrad C; Fleischer A; Laquer VT; Misery L; Serra-Baldrich E; Lapeere H; Ahmad F; Jabbar Lopez ZK; Piketty C; Ständer S;
    N Engl J Med; 2023 Oct; 389(17):1579-1589. PubMed ID: 37888917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A critical evaluation of nemolizumab for prurigo nodularis.
    Brooks SG; Yosipovitch G
    Expert Rev Clin Immunol; 2024 Jun; 20(6):577-587. PubMed ID: 38217530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nemolizumab for atopic dermatitis.
    Labib A; Vander Does A; Yosipovitch G
    Drugs Today (Barc); 2022 Apr; 58(4):159-173. PubMed ID: 35412530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.
    Kabashima K; Matsumura T; Komazaki H; Kawashima M;
    N Engl J Med; 2020 Jul; 383(2):141-150. PubMed ID: 32640132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-31 and Pruritic Skin.
    Furue M; Furue M
    J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33924978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-31 and interleukin-31 receptor: New therapeutic targets for atopic dermatitis.
    Nakashima C; Otsuka A; Kabashima K
    Exp Dermatol; 2018 Apr; 27(4):327-331. PubMed ID: 29524262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody.
    Oyama S; Kitamura H; Kuramochi T; Higuchi Y; Matsushita H; Suzuki T; Goto M; Adachi H; Kasutani K; Sakamoto A; Iwayanagi Y; Kaneko A; Nanami M; Fujii E; Esaki K; Takashima Y; Shimaoka S; Hattori K; Kawabe Y
    Exp Dermatol; 2018 Jan; 27(1):14-21. PubMed ID: 27714851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-cell profiling of prurigo nodularis demonstrates immune-stromal crosstalk driving profibrotic responses and reversal with nemolizumab.
    Ma F; Gharaee-Kermani M; Tsoi LC; Plazyo O; Chaskar P; Harms P; Patrick MT; Xing X; Hile G; Piketty C; Lazzari A; Van Delm W; Maverakis E; Nakamura M; Modlin RL; Kahlenberg JM; Billi AC; Julia V; Krishnaswamy JK; Gudjonsson JE
    J Allergy Clin Immunol; 2024 Jan; 153(1):146-160. PubMed ID: 37506977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.
    Ruzicka T; Hanifin JM; Furue M; Pulka G; Mlynarczyk I; Wollenberg A; Galus R; Etoh T; Mihara R; Yoshida H; Stewart J; Kabashima K;
    N Engl J Med; 2017 Mar; 376(9):826-835. PubMed ID: 28249150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies.
    Kabashima K; Matsumura T; Komazaki H; Kawashima M;
    Br J Dermatol; 2022 Apr; 186(4):642-651. PubMed ID: 34726262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.
    Silverberg JI; Pinter A; Pulka G; Poulin Y; Bouaziz JD; Wollenberg A; Murrell DF; Alexis A; Lindsey L; Ahmad F; Piketty C; Clucas A
    J Allergy Clin Immunol; 2020 Jan; 145(1):173-182. PubMed ID: 31449914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study.
    Kabashima K; Furue M; Hanifin JM; Pulka G; Wollenberg A; Galus R; Etoh T; Mihara R; Nakano M; Ruzicka T
    J Allergy Clin Immunol; 2018 Oct; 142(4):1121-1130.e7. PubMed ID: 29753033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-31 as a Clinical Target for Pruritus Treatment.
    Kabashima K; Irie H
    Front Med (Lausanne); 2021; 8():638325. PubMed ID: 33644103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prurigo nodularis: new insights into pathogenesis and novel therapeutics.
    Liao V; Cornman HL; Ma E; Kwatra SG
    Br J Dermatol; 2024 May; 190(6):798-810. PubMed ID: 38345154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of Neuroimmune and Epithelial Dysregulation in Patients With Moderate to Severe Prurigo Nodularis Treated With Nemolizumab.
    Deng J; Liao V; Parthasarathy V; Cornman HL; Kambala A; Kwatra MM; Ständer S; Piketty C; Chaskar P; Krishnaswamy JK; Julia V; Kwatra SG
    JAMA Dermatol; 2023 Sep; 159(9):977-985. PubMed ID: 37556125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.